NASDAQ:LBRX
Lb Pharmaceuticals Inc.
Lb Pharmaceuticals Inc. reported net income of −$25.2M in fiscal 2025. Free cash flow was −$35.3M, and the diluted share count rose 2145.8%.Summary generated from Lb Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−24.4%
Debt / equityn/a
Free cash flow−$35.3M
FCF marginn/a
Share count change+2145.8%
Financials
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | n/a | n/a |
| Operating income | n/a | n/a |
| Net income | −63 | −25 |
| Free cash flow | −54 | −35 |
Recent filings
- 8-KDirector or officer change
Sep 15, 2026 - 8-KDirector or officer change
Sep 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 4Insider transaction report
Aug 3, 2026 - 8-KEntry into a material agreement
Jul 29, 2026 - 8-KOther events
Jul 22, 2026 - 8-KDirector or officer change
Jun 10, 2026